We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ABIOMED Impella Data Show Significant Rise in Survival Rates
Read MoreHide Full Article
ABIOMED, Inc.’s flagship Impella has been proved to significantly increase cardiogenic shock survival and heart recovery in patients. Data exhibits that survival rates have increased from 51% to 67% since the device’s FDA Pre Market Approval for treating cardiogenic shock.
However, this latest development could not drive the Zacks Rank #2 (Buy) stock’s shares, which lost 0.5% to $282.87 at close.
Notably, this latest development fortifies the MedTech giant’s foothold in the U.S. cardiovascular devices market.
Impella in Focus
Impella, the world’s smallest heart pump, is ABIOMED’s flagship product line. The company’s Impella 2.5, Impella RP, Impella 5.0 and Automated Impella Controller deserve a mention in this regard.
Notably, the product has been driving the company’s top line since inception.
Management confirmed that ABIOMED is currently investing in the commercial distribution to prepare for the expansion of Impella CP, Impella Connect, Impella 5.5 and Impella RP.
Interestingly, ABIOMED’s new technology called Impella Connect has been launched at 36 U.S. hospitals in recent times.
In the last reported quarter, Impella heart pump revenues jumped 31% year over year.
Market Prospects
Per research by CDC, nearly 610,000 people die of heart diseases each year in the United States.
Statista validates that the U.S. cardiovascular devices market is expected to reach a worth of $15.7 billion by 2021.
Thus, the latest development has been a well-timed one for ABIOMED.
Price Performance
We believe positive developments such as these would drive the shares of ABIOMED which have declined 3.2% against the industry’s 13.6% rally in a year’s time. The current level also compares unfavorably with the S&P 500 index’s 8% rise.
Varian Medical’s long-term earnings growth is projected at 8%.
Masimo’s long-term earnings are expected to grow 15.6%.
Penumbra’s long-term earnings growth rate is estimated at 20.9%.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
Image: Bigstock
ABIOMED Impella Data Show Significant Rise in Survival Rates
ABIOMED, Inc.’s flagship Impella has been proved to significantly increase cardiogenic shock survival and heart recovery in patients. Data exhibits that survival rates have increased from 51% to 67% since the device’s FDA Pre Market Approval for treating cardiogenic shock.
However, this latest development could not drive the Zacks Rank #2 (Buy) stock’s shares, which lost 0.5% to $282.87 at close.
Notably, this latest development fortifies the MedTech giant’s foothold in the U.S. cardiovascular devices market.
Impella in Focus
Impella, the world’s smallest heart pump, is ABIOMED’s flagship product line. The company’s Impella 2.5, Impella RP, Impella 5.0 and Automated Impella Controller deserve a mention in this regard.
Notably, the product has been driving the company’s top line since inception.
Management confirmed that ABIOMED is currently investing in the commercial distribution to prepare for the expansion of Impella CP, Impella Connect, Impella 5.5 and Impella RP.
Interestingly, ABIOMED’s new technology called Impella Connect has been launched at 36 U.S. hospitals in recent times.
In the last reported quarter, Impella heart pump revenues jumped 31% year over year.
Market Prospects
Per research by CDC, nearly 610,000 people die of heart diseases each year in the United States.
Statista validates that the U.S. cardiovascular devices market is expected to reach a worth of $15.7 billion by 2021.
Thus, the latest development has been a well-timed one for ABIOMED.
Price Performance
We believe positive developments such as these would drive the shares of ABIOMED which have declined 3.2% against the industry’s 13.6% rally in a year’s time. The current level also compares unfavorably with the S&P 500 index’s 8% rise.
Other Key Picks
Other top-ranked stocks in the broader medical space are Varian Medical Systems , Masimo Corporation (MASI - Free Report) and Penumbra, Inc. (PEN - Free Report) , each carrying a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Varian Medical’s long-term earnings growth is projected at 8%.
Masimo’s long-term earnings are expected to grow 15.6%.
Penumbra’s long-term earnings growth rate is estimated at 20.9%.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>